Cellular engineering for therapeutic protein production: product quality, host modification, and process improvement

Area of Science:

• Biochemistry
• Cell Biology
• Bioengineering
• Biopharmaceutical Manufacturing

Background:

• Recombinant proteins offer therapeutic advantages over small molecules but face production challenges.
• Cellular synthesis is complex, driving innovation in biologic drug development.
• Escherichia coli, Saccharomyces cerevisiae, and Chinese hamster ovary (CHO) cells are primary hosts for recombinant protein expression.

Purpose of the Study:

• To review recent developments in improving recombinant protein production.
• To compare advancements in E. coli, S. cerevisiae, and CHO systems.
• To highlight the framework for future discoveries in therapeutic protein manufacturing.

Main Methods:

• Review of novel expression cassettes and cell line modifications.
• Analysis of engineered secretion pathways and media design improvements.
• Comparison of recent advancements against established knowledge in protein production.

Main Results:

• Significant improvements in protein production yields and quality across key host systems.
• Enhanced efficiency and cost-effectiveness in biopharmaceutical manufacturing.
• Identification of key strategies for optimizing recombinant protein expression.

Conclusions:

• Ongoing innovations in protein production are crucial for the expanding field of therapeutic biologics.
• Optimized production systems will lead to safer, more efficient, and affordable drugs.
• These advancements provide a foundation for future breakthroughs in biopharmaceutical development.